OBJECTIVE: To determine the effect of immunoglobulin (Ig)M-enriched Ig therapy on mortality rate and renal function in sepsis-induced multiple organ dysfunction syndrome (MODS), using the Acute Physiology and Chronic Health Evaluation II (APACHE II) score. METHODS: Retrospective study of patients with sepsis-induced MODS treated with standard antibiotic plus supportive therapy (control group) or IgM-enriched Ig therapy adjuvant to control group therapy (IVIg group). Total length of stay in the intensive care unit (ICU), overall mortality rate and 28-day case fatality rate (CFR), as well as APACHE II scores and renal function parameters at day 1 and day 4 of therapy, were recorded. RESULTS: A total of 118 patients were included (control group, n = 62; IVIg group, n = 56). In both groups, day 4 APACHE II scores decreased significantly compared with day 1 scores; the effect of treatment on renal function was minimal. Length of ICU stay, overall mortality rate and 28-day CFR were significantly lower in the IVIg group compared with the control group. CONCLUSIONS: Adding IgM-enriched Ig therapy to standard therapy for MODS improved general clinical conditions and significantly reduced APACHE II scores, overall mortality rate and 28-day CFR, although effects on renal function were minimal. KEY WORDS: MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS); SEPSIS; MORTALITY; IGM-ENRICHED IMMUNOGLOBULIN; APACHE II SCORE L Yavuz, G Aynali, A Aynali et al. IgM-enriched Ig therapy for sepsis-induced MODS
Introduction
Sepsis is a clinical syndrome presenting with infection, inflammation and widespread tissue injury. 1, 2 Organ function is impaired unless tissue injury and multiple organ dysfunction syndrome (MODS; defined as a clinical condition including insufficiency of two or more organ systems) are prevented. 3 Pulmonary, liver and kidney failure have a direct effect on morbidity and mortality, as well as on length of stay in the intensive care unit (ICU); in addition, the kidneys and liver are the most important organs affected in sepsis. 4 -6 Acute renal injury is a frequent and serious complication of sepsis in ICU patients and is associated with a very high mortality rate. 7 Standard management for sepsis or sepsisinduced MODS includes general supportive treatment, such as nutrition support, management protocols for organ failure and antimicrobial treatment. New adjuvant therapies that play modulating roles in the inflammatory response to sepsis have been used to decrease mortality. In this regard, immunoglobulins (Ig) are reported to be very effective. 8 -11 The use of intravenous Ig (IVIg) is a relatively novel therapy to modulate the immune response in sepsis and may exert beneficial effects by several mechanisms. 12 -14 IgG and IgM serum levels are diminished in patients with sepsis and can act as good prognostic factors in many cases. 15 Additionally, the neutralizing effect of IgM is greater than that for other Ig, and IgM administration can significantly reduce the incidence of postoperative infection. 16 Various scoring systems have been developed and used in order to classify the severity of disease in patients entering the ICU. 17 -20 The most successful scoring system for monitoring MODS in the ICU is the Acute Physiology and Chronic Health Evaluation II (APACHE II) system. 20 The present retrospective study determined the effects of standard therapy alone and together with adjuvant IgM-enriched IVIg therapy on the APACHE II score, as well as on mortality and renal function, in patients with sepsisinduced MODS. This was not a randomized controlled study because administration of IVIg treatment was dependent on its market availability at the time, as well as on the ability for such treatment to be financed by the governmental Health Insurance Services of Turkey. When IVIg therapy was unavailable, only supportive management was administered to patients with sepsisinduced MODS.
Patients and methods

STUDY POPULATION
This retrospective study was conducted at Süleyman Demirel University Hospital, Isparta, Turkey, which is a tertiary care facility with 18 ICU beds. Data collected on all patients admitted to the medical-surgical ICU between January 2004 and December 2010 were reviewed, to identify those who were diagnosed with sepsis-induced MODS during their ICU stay. Patients were diagnosed with MODS in cases of dysfunction of a minimum of two organ systems, using the following definitions: (i) dysfunction of the respiratory system, defined as a requirement for assisted ventilation to maintain adequate gas exchange, including oxygenation and eliminating carbon dioxide; (ii) dysfunction of the cardiovascular system, defined as hypotension, low or marginal cardiac output, or general inadequate circulation that required pharmacological circulatory assistance; (iii) renal dysfunction, defined as the inability of the kidneys to regulate urinary volume, maintain electrolyte concentrations or remove waste products; and (iv) hepatic dysfunction, defined as L Yavuz, G Aynali, A Aynali et al. IgM-enriched Ig therapy for sepsis-induced MODS elevated bilirubin level, elevated hepatic enzyme levels and end-stage hepatic coma. Disease severity was determined using the APACHE II survival probability score (APACHE II scores were estimated online at http://www.sfar.org/scores2/apache22.html# grad, and scored on a scale of 0 -71).
Those ICU patients treated solely with supportive management during the study period were included in the control group. In the same time period, patients who also received IgM-enriched IVIg therapy were included in the IVIg group. Inclusion criteria were: existence of systemic inflammatory response syndrome (defined as the presence of at least two of the following parameters: temperature > 38°C or < 36°C; heart rate > 90 beats/min; respiratory rate > 20 breaths/min or partial pressure of carbon dioxide in blood < 32 mmHg; white blood cell count > 12 000/mm 3 or < 4000/mm 3 ); at least one proven infection focus; at least one positive blood culture for Gram-negative or Gram-positive bacteria; antibiotic therapy; at least two organ system failures; APACHE II score > 25. Cases with malignant disease and chronic renal failure were excluded from the study.
The study was approved by the Scientific Research Projects Advisory Board of Süleyman Demirel University, Isparta, Turkey (reference No. 09.02.2011/XX/3). Informed consent was waived and data were obtained in an anonymous manner.
STUDY TREATMENTS
Patients diagnosed with sepsis-induced MODS were divided into two groups according to the therapy that was administered, commencing on the day that sepsis-induced MODS was diagnosed (day 1). The control group received supportive management (including standard antibiotic therapy). The IVIg group received the standard antibiotic therapy and supportive management, with the addition of 5 ml/kg polyvalent IVIg (Pentaglobin ® ; Biotest AG, Dreieich, Germany), administered by daily intravenous infusion for 3 consecutive days.
Supportive management was conducted according to the practice treatment guidelines of Süleyman Demirel University Hospital for sepsis-induced MODS and consisted of fluid resuscitation, vasoactive drugs and respiratory support. For fluid resuscitation, central venous pressure monitoring and vasoactive drugs were used, unless the fluid treatment achieved the adequate arterial pressure (mean arterial pressure ≥ 60 mmHg). Respiratory support and lung protective mechanical ventilation strategies (6 -8 ml/kg tidal volume, maximum 15 cmH 2 O positive end expiratory pressure, 30 mmHg peak airway pressure and frequency of 22 breaths/min) were used for patients with sepsis who developed acute lung injury or acute respiratory distress syndrome. Tracheotomy was performed on patients who received respiratory treatment for ≥ 10 days. All patients were evaluated at the Infectious Diseases Clinic (Süleyman Demirel University) for control of infection foci and for antibiotic choice, dosage, therapy schedule and combination regimens.
DATA COLLECTION
All data for the study were retrieved from archived patient records. Data were retrieved from the time that therapy was initiated (day 1) and for parameters where follow-up data were available, 96 h later (day 4). Demographic and clinical data collected for both groups included: age; gender; admission category; affected organ systems; total length of stay in the ICU; overall mortality rate; number of patients who died within 28 days of initiation of therapy (28- L Yavuz, G Aynali, A Aynali et al.
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day case fatality rate [CFR]); number of days from therapy initiation to death. Detailed biochemical and haematological tests were performed routinely on a daily basis in the study clinic for all critical MODS cases. The day 1 and day 4 data on all such routine biochemical and haematological tests were retrieved for all patients included in the study. APACHE II scores on days 1 and 4 were also obtained. Details of bacteria isolated from the patients' blood, and features of Gram-negative and Gram-positive bacteria that led to sepsis-induced MODS, were also collected. In order to assess renal function, data on blood creatinine and blood urea nitrogen (BUN) were retrieved. Patients were followed-up from admission to the ICU until discharge; 28-day CFR and overall mortality rate were recorded only for patients who died while still in the ICU.
STATISTICAL ANALYSES
The Kruskal-Wallis test was used to analyse age, total length of ICU stay and days to death. Gender, admission category, overall mortality rate, 28-day CFR and betweengroup distribution of organ dysfunction were analysed using Pearson's χ 2 -test. Comparisons of initial BUN and creatinine levels, and APACHE II scores, were performed using the Kruskal-Wallis test. Variations between the two therapy time points (days 1 and 4) were determined using the Wilcoxon signed-rank test. A P-value of < 0.05 was considered to be statistically significant.
Results
Based on digital archive data, 1548 patients were admitted to the ICU between January 2004 and December 2010. Overall, 118 patients between 15 and 88 years old, diagnosed with sepsis-induced MODS, were identified retrospectively; 62 patients were included in the control group and 56 in the IVIg group.
Demographic and clinical characteristics of all patients at day 1 are shown in Table 1 . There were no significant between-group differences in age, gender, admission category or bacterial Gram species (positive/negative) isolated. The distribution of organ systems in which dysfunction developed is shown in Table 1 . The number of patients with organ dysfunction in two organs was significantly higher in the control group than in the IVIg group (P = 0.038), and the number of patients with organ dysfunction in three organs was higher in the IVIg group than in the control group, although this difference was not statistically significant.
At day 1, the groups were not significantly different in terms of APACHE II scores or renal function (BUN and creatinine levels) ( Table 2 ). APACHE II scores were significantly lower on day 4 versus day 1 within both treatment groups (P ≤ 0.001). BUN and creatinine levels were similar on days 1 and 4 in the control group. BUN levels were also similar in the IVIg group on days 1 and 4, although a significant reduction in creatinine levels was observed on day 4 versus day 1 in this group (P = 0.013), suggesting a small effect on renal function.
Total length of stay in the ICU was significantly longer for the IVIg group versus the control group (P = 0.002) ( Table 3 ). There was no significant difference in the number of days to death between the two groups. The overall mortality rate and 28-day CFR were both significantly higher in the control group than in the IVIg group (P < 0.0001).
Discussion
Many factors affect clinical conditions and mortality in MODS, including the number of affected organs and the degree of organ dysfunction. 21 The previously reported L Yavuz, G Aynali, A Aynali et al.
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mortality range for MODS varies between 30% and 80%. 21 -25 The number of organ systems that develop insufficiency, and the degree of insufficiency, may account for this wide range. Additionally, delaying treatment or receiving inadequate supportive treatment both elevate the overall mortality rate. Development of MODS is inevitable unless early and effective treatment is achieved. Sepsis is the inflammatory response of the body to severe infection, which can be caused by a variety of bacteria. Death rates due to sepsis and septic shock remain high despite giving antibiotics, especially if vital organs such as the lungs, heart and kidney are affected. Sepsis has been described as an imbalance between the proinflammatory reaction and antiinflammatory response; 22 thus, immunological therapy such as IVIg has been used in recent years for sepsis-induced MODS.
The IVIg preparations contain antibodies that help the body to neutralize bacterial toxins. There are two types of preparations: polyclonal Ig (containing several antibodies), and monoclonal Ig (targeting a specific antigen). 26 In one study, IVIg therapy hindered complement activation. 27 Thus, Ig therapy (especially polyclonal Ig) supports the immune system. A retrospective analysis from 2010, in 20 subjects receiving IVIg therapy, failed to detect a positive therapeutic effect in the hepatorenal system, although an improvement in APACHE II 3 The clinical effectiveness of IVIg therapy for sepsis is very good in MODS, and we believe that the reduction in APACHE II scores seen after treatment indicates this, although three-organ involvement was more frequent in cases where IVIg therapy was applied. 3 The overall mortality rate and 28-day CFR in the present study were significantly lower in patients receiving IVIg therapy in addition to standard therapy compared with those receiving standard therapy alone, further supporting the effectiveness of this therapy for MODS.
Sepsis and septic shock remain the most important triggers of acute renal failure in ICU patients. Despite the advent of sophisticated renal replacement therapies that employ high-dose haemofiltration and high-flux membranes, mortality and morbidity from sepsis-induced acute kidney injury remain high. 7 Sepsis-related acute renal failure has a much higher mortality rate than acute renal failure without sepsis. A possible explanation for the high incidence and poor outcome of septic acute renal failure relates to the lack of specific therapies 28 and a limited understanding of sepsis-related acute kidney injury and its pathogenesis. 29 In the present study, a nonsignificant improvement in the BUN level and a significant reduction in the creatinine level were observed on day 4, in patients receiving IVIg therapy. Although the number of patients who developed acute renal dysfunction was significantly higher in the IVIg group than in the control group, the improvements in BUN and creatinine levels indicated a positive effect of IVIg therapy on renal function.
Both clinically and economically, IVIg is a promising adjuvant therapy for the treatment of adults with severe sepsis and sepsis-induced MODS. In the present study, IgM-enriched Ig therapy adjuvant to standard therapy improved the patients' clinical conditions. According to APACHE II scores, both therapies were effective, although effects were more pronounced in the IVIg group. This clinical improvement led to significant reductions in the overall mortality rate and 28-day CFR. There were, however, some limitations to the present study.
The study was conducted retrospectively due to lack of availability of IVIg (caused by an unpredictable supply, import regulations and the high cost of this therapy). This, together with the fact that the treatment of patients was conducted by different physicians during different time periods, makes it difficult to compare the two treatment groups.
In conclusion, adding IgM-enriched Ig therapy to standard therapy for sepsisinduced MODS improved the general clinical condition of patients and provided significant reductions in APACHE II scores, overall mortality rates and 28-day CFRs, compared with standard therapy alone. Additionally, the effects on renal function appeared to be minimal.
